Leprosy tertiary prevention: Difference between revisions
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
| Line 5: | Line 5: | ||
==Tertiary Prevention== | ==Tertiary Prevention== | ||
Once an individual is [[infected]] with leprosy and [[symptoms]] start to develop, the longer the period to establish the correct [[diagnosis]] and [[Therapy|treatment]] is started, greater the chance of developing lifetime [[nerve damage]], [[skin]] and [[body]] in general. | Once an individual is [[infected]] with leprosy and [[symptoms]] start to develop, the longer the period to establish the correct [[diagnosis]] and [[Therapy|treatment]] is started, greater the chance of developing lifetime [[nerve damage]], [[skin]] and [[body]] in general. It is important to stress this time frame because, even after the diagnosis has been reached and multiple drug therapy has been started, significant nerve damage will continue to develop, | ||
T and after the patient has completed the full course of MDT; the risk declines steadily over the following three years. MB cases with impaired nerve function at diagnosis are at much higher risk of nerve damage than other patients and, therefore, should be monitored more closely | |||
==References== | ==References== | ||
Revision as of 04:25, 6 July 2014
|
Leprosy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Leprosy tertiary prevention On the Web |
|
American Roentgen Ray Society Images of Leprosy tertiary prevention |
|
Risk calculators and risk factors for Leprosy tertiary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Tertiary Prevention
Once an individual is infected with leprosy and symptoms start to develop, the longer the period to establish the correct diagnosis and treatment is started, greater the chance of developing lifetime nerve damage, skin and body in general. It is important to stress this time frame because, even after the diagnosis has been reached and multiple drug therapy has been started, significant nerve damage will continue to develop,
T and after the patient has completed the full course of MDT; the risk declines steadily over the following three years. MB cases with impaired nerve function at diagnosis are at much higher risk of nerve damage than other patients and, therefore, should be monitored more closely